Carr Financial Group Corp Acquires 293 Shares of Novo Nordisk A/S (NYSE:NVO)

Carr Financial Group Corp grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 14.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,393 shares of the company’s stock after buying an additional 293 shares during the period. Carr Financial Group Corp’s holdings in Novo Nordisk A/S were worth $206,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of NVO. Xponance Inc. grew its stake in shares of Novo Nordisk A/S by 27.6% during the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after buying an additional 576 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after buying an additional 9,012 shares during the last quarter. Daymark Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 15.9% during the second quarter. Daymark Wealth Partners LLC now owns 6,290 shares of the company’s stock valued at $898,000 after buying an additional 864 shares during the last quarter. Maverick Capital Ltd. grew its stake in shares of Novo Nordisk A/S by 272.9% during the second quarter. Maverick Capital Ltd. now owns 7,849 shares of the company’s stock valued at $1,120,000 after buying an additional 5,744 shares during the last quarter. Finally, Matrix Private Capital Group LLC grew its stake in shares of Novo Nordisk A/S by 7.9% during the second quarter. Matrix Private Capital Group LLC now owns 1,757 shares of the company’s stock valued at $251,000 after buying an additional 129 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $87.94 on Friday. The firm has a market capitalization of $394.65 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a fifty day moving average of $95.62 and a 200 day moving average of $115.55. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.